Tratamiento biológico de la artritis reumatoide en España. Análisis de impacto presupuestario de la utilización de certolizumab pegol

Hidalgo, Álvaro; Villoro, Renata; Ivanova, Alexandra; Morell, A.; Talavera, Pablo; Ferro, B

doi:10.1007/s40277-013-0019-2

Cited by 2 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La inclusión de medidas de costes consta de tres partes fundamentales: la identificación de los costes a incluir, la medición de las unidades utilizadas de cada recurso, y la asignación de un valor económico a cada ítem o recurso. Las siguientes secciones abarcan brevemente estos temas, a pesar que estos aspectos ya han sido tratados en el cuaderno número 4 los comentaremos brevemente aquí (Hidalgo et al 2013).…”

Section: Condición De Igualdad O Equivalencia De Resultadosunclassified

“…Un ejemplo reciente de la importancia de incluir costes diferentes a los farmacológicos se encuentra en Hidalgo et al (2013). En este estudio se muestra que en los protocolos de administración de fármacos antirreumáticos, el coste farmacológico anual por paciente de las inyecciones subcutáneas de algunos tratamientos puede ser más elevado que el de algunas infusiones intravenosas.…”

Section: Tipos De Costes a Incluirunclassified

“…Por lo tanto, cuando se calculan los costes totales de administración, formación y monitorización, se evidencia un menor coste para el hospital en los regímenes de inyecciones subcutáneas, debido principalmente al elevado coste de administración que generan las infusiones intravenosas (Tabla 1). Fuente: Elaboración propia a partir de datos de Hidalgo et al (2013).…”

Section: Tipos De Costes a Incluirunclassified

See 2 more Smart Citations

Cuadernos de Evaluación Sanitaria. Nº 6. Modelos de evaluación económica y su aplicación en España

Hidalgo¹,

Llano²

2011

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Condición De Igualdad O Equivalencia De Resultadosunclassified

Section: Tipos De Costes a Incluirunclassified

See 1 more Smart Citation

Cuadernos de Evaluación Sanitaria. Nº 6. Modelos de evaluación económica y su aplicación en España

Hidalgo¹,

Llano²

2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…The implications of our study findings for the public payer in Spain suggest that the Spanish NHS would be adopting the most cost-effective treatment if certolizumab pegol were offered to RA patients in combination with methotrexate instead of alternative TNF inhibitors currently recommended in Spain. Furthermore a recent study, in that equality of effectiveness is supposed, indicated that the addition of certolizumab pegol on the NHS in Spain, would generate large net savings of €10.3 million for the period 2013 to 2017 [ 60 ].…”

Section: Discussionmentioning

confidence: 99%

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Hidalgo

Villoro

Blasco³

et al. 2015

Cost Eff Resour Alloc

Self Cite

View full text Add to dashboard Cite

BackgroundCertolizumab pegol, a PEGylated tumour necrosis factor (TNF)-inhibitor, improves the clinical signs and symptoms of rheumatoid arthritis (RA) when used in combination with methotrexate or as monotherapy. This study evaluatedthe cost-utility of certolizumab pegol versusTNF-inhibitors plus methotrexate in the treatment of moderate-to-severe RA in Spain.MethodsA Markov cohort health state transition model was developed to evaluate the cost-utility (costs and quality-adjusted life years [QALYs]) of certolizumab pegol versus other TNF-inhibitors licensed in Spain in 2009. Efficacy was measured using the American College of Rheumatology (ACR) responses at 6 months, based on adjusted indirect comparisons from published clinical trials. Utilities were derived from EQ-5D data from certolizumab pegol RA clinical trials. Clinical history and resource use data came from published literature. Unit costs were taken from Spanish databases or published data (cost year 2009). Base case analyses were conducted from the payer perspective, with a lifetime horizon, 3.5 % annual discounting rates for costs and outcomes, and 3 % inflation rate for 2009 onwards. One-way sensitivity analyses were conducted.ResultsThe average lifetime costs for certolizumab pegol, etanercept, adalimumab (every 2 weeks and weekly) and infliximab (3 mg/kg and 5 mg/kg) in combination with methotrexate were €140,971, €141,197, €139,148, €164,741, €136,961 and €152,561, respectively. The QALYs gained were 6.578, 6.462, 6.430 (for both adalimumab doses), 6.430, and 6.318 (for both infliximab doses), respectively. At a €30,000/QALY willingness-to-pay threshold, certolizumab pegol plus methotrexate dominated adalimumab weekly, etanercept, and infliximab 5 mg/kg, and was cost-effective versus adalimumab every 2 weeks and infliximab 3 mg/kg (all with methotrexate), with estimated ICERs of €12,346/QALY and €15,414/QALY, respectively. Certolizumab pegol monotherapy was more cost-effective versus adalimumab, and less expensive with similar health gains versus etanercept (6.416 QALYs vs 6.492). Univariate analysis showed ICERs to be sensitive to changes in time horizon, ACR response time point, baseline Heath Assessment Questionnaire (HAQ) score, and rate of HAQ-disability index deterioration after discontinuing treatment.ConclusionsThis analysis shows that certolizumab pegol is cost-effective compared with other TNF-inhibitors recommended in Spain for the treatment of RA.

show abstract

Tratamiento biológico de la artritis reumatoide en España. Análisis de impacto presupuestario de la utilización de certolizumab pegol

Cited by 2 publications

References 13 publications

Cuadernos de Evaluación Sanitaria. Nº 6. Modelos de evaluación económica y su aplicación en España

Cuadernos de Evaluación Sanitaria. Nº 6. Modelos de evaluación económica y su aplicación en España

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Contact Info

Product

Resources

About